Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
C 0.38 -5.97% -0.02
GLYC closed down 5.97 percent on Friday, November 1, 2024, on 16 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Earnings Movers Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Parabolic Rise Strength -5.97%
Upper Bollinger Band Walk Strength -5.97%
Wide Bands Range Expansion -5.97%
Upper Bollinger Band Touch Strength -5.97%

   Recent Intraday Alerts

Alert Time
Down 5% about 19 hours ago
Possible Inside Day about 19 hours ago
60 Minute Opening Range Breakdown about 20 hours ago
Up 3% about 23 hours ago
Up 2% about 23 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GlycoMimetics, Inc. Description

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Drug Discovery Acute Myeloid Leukemia Chemotherapy Clinical Trial Product Testing Hematologic Cancers Pseudomonas Sickle Cell Disease Nursing Research

Is GLYC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.5299
52 Week Low 0.1406
Average Volume 24,390,377
200-Day Moving Average 1.15
50-Day Moving Average 0.19
20-Day Moving Average 0.21
10-Day Moving Average 0.28
Average True Range 0.05
RSI (14) 69.97
ADX 39.58
+DI 53.50
-DI 8.11
Chandelier Exit (Long, 3 ATRs) 0.47
Chandelier Exit (Short, 3 ATRs) 0.30
Upper Bollinger Bands 0.44
Lower Bollinger Band -0.01
Percent B (%b) 0.88
BandWidth 209.64
MACD Line 0.06
MACD Signal Line 0.03
MACD Histogram 0.0301
Fundamentals Value
Market Cap 24.64 Million
Num Shares 64.4 Million
EPS -0.63
Price-to-Earnings (P/E) Ratio -0.61
Price-to-Sales 1154.60
Price-to-Book 4.57
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.45
Resistance 3 (R3) 0.46 0.44 0.44
Resistance 2 (R2) 0.44 0.42 0.44 0.44
Resistance 1 (R1) 0.41 0.41 0.40 0.41 0.43
Pivot Point 0.39 0.39 0.39 0.39 0.39
Support 1 (S1) 0.36 0.38 0.36 0.36 0.33
Support 2 (S2) 0.35 0.36 0.34 0.33
Support 3 (S3) 0.32 0.35 0.33
Support 4 (S4) 0.31